Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357004 | 1.00 | GCK (0.53) | GCKMEN1NPC1CASP3RAB9A | |
| SCHEMBL29354520 | 0.88 | MEN1 (0.53) | GCKMEN1NPC1CASP3RAB9A | |
| SCHEMBL21394759 | 0.88 | MEN1 (0.53) | GCKMEN1NPC1CASP3RAB9A | |
| SCHEMBL21394910 | 0.86 | NPC1 (0.50) | GCKMEN1NPC1CASP3RAB9A | |
| SCHEMBL29356894 | 0.86 | NPC1 (0.50) | GCKMEN1NPC1CASP3RAB9A | |
| SCHEMBL21394682 | 0.81 | ALDH1A1 (0.47) | GCKMEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL29354654 | 0.81 | ALDH1A1 (0.47) | GCKMEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL29357070 | 0.79 | L3MBTL1 (0.47) | GCKMEN1NPC1CASP3RAB9A | |
| SCHEMBL21394806 | 0.79 | L3MBTL1 (0.47) | GCKMEN1NPC1CASP3RAB9A | |
| SCHEMBL24932144 | 0.78 | ALDH1A1 (0.52) | GCKMEN1NPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| CN-118084800-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084801-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112312913-B | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-22 | — | — | US | disclosed |
| CN-114174273-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-112312913-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | GCK 4257/4885MEN1 191/4885NPC1 196/4885 |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | GCK 3525/4885MEN1 1807/4885NPC1 72/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | GCK 3525/4885MEN1 1807/4885NPC1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.